$RXST News

RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

RxSight, Inc. (RXST) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9

Needham Maintains Buy on RxSight, Lowers Price Target to $11

RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction

RxSight Affirms FY2026 Sales Guidance of $120.000M-$135.000M vs $129.182M Est

How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets

RxSight, Inc. to Present at the Bank of America Healthcare Conference

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference

Stifel Maintains Hold on RxSight, Lowers Price Target to $9

What 5 Analyst Ratings Have To Say About RxSight

UBS Maintains Neutral on RxSight, Raises Price Target to $9

RxSight, Inc. Q4 2025 Earnings Call Summary

Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $10

RxSight shares are trading lower after the company reported Q4 financial results and issued FY26 sales guidance with its midpoint below estimates. Also, Wells Fargo maintained an Equal-Weight rating on the stock but lowered its price target from $13 to $11.

RxSight shares are trading lower after the company reported Q4 financial results and issued FY26 sales guidance with its midpoint below estimates. Also, Wells Fargo maintained an Equal-Weight rating on the stock but lowered its price target from $13 to $11.